NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) today announced the release of a white paper titled “StereoCED™ - A Scalable Platform for CNS Drug Delivery,” available for download from the Scientific Resources section of nmtc1.com or here. The paper outlines how the company’s StereoCED™ platform is designed to overcome key barriers to the commercial delivery of brain therapeutics by leveraging existing robotic stereotactic systems.
As advances in cell and gene therapies, biologics, and other central nervous system (CNS) therapeutics increase the demand for efficient, reproducible methods of delivering therapies directly to the brain, convection-enhanced delivery (CED) has shown promise in bypassing the blood-brain barrier and achieving targeted drug distribution. However, current approaches often involve lengthy sequential infusions and specialized workflows that may become impractical as therapies expand into broader commercial use. The StereoCED™ platform aims to address these challenges by supporting simultaneous, multi-trajectory intracranial drug delivery through a streamlined robotic workflow, potentially reducing procedure time while enabling reproducible, scalable therapeutic delivery.
Dave Rosa, President and Chief Executive Officer of NeuroOne, stated, “Brain-delivered therapeutics are approaching an important inflection point. As these therapies move toward commercialization, certain intracranial infusion procedures lasting 8 to 12 hours may become a significant bottleneck to commercial adoption. We believe healthcare systems will need solutions that leverage established neurosurgical workflows, significantly reduce procedure time, and support scalable delivery across hospitals. StereoCED™ is being designed with those needs in mind, and we look forward to device availability for research and investigational clinical studies by fiscal year-end.”
The white paper highlights that the StereoCED™ drug delivery platform is currently under development and has not been cleared or approved by the U.S. Food and Drug Administration for commercialization. NeuroOne is a medical technology company focused on improving surgical care options and outcomes for patients with neurological disorders, marketing a minimally invasive and high-definition electrode technology platform with four FDA-cleared product families: Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation System (for brain), and OneRF® Trigeminal Nerve Ablation System. The company is also engaged in research and development for drug delivery, basivertebral nerve ablation, and spinal cord stimulation programs.
This announcement comes as NeuroOne prepares for device availability for research and investigational clinical studies by the end of its fiscal year, potentially paving the way for a new standard in CNS drug delivery that could significantly impact the treatment landscape for neurological disorders.
